Literature DB >> 8822944

A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia.

A Hochhaus1, A Reiter, H Skladny, J V Melo, C Sick, U Berger, J Q Guo, R B Arlinghaus, R Hehlmann, J M Goldman, N C Cross.   

Abstract

A novel variant of the chimeric BCR-ABL mRNA transcript was detected in a patient with Philadelphia chromosome-negative (Ph-) chronic myelogenous leukemia (CML) by multiplex reverse-transcription polymerase chain reaction (RT-PCR). Sequence analysis of the fusion region of the amplified cDNA fragment showed an in-frame joining of exon e6 of the BCR gene and exon a2 of the ABL gene, giving rise to an e6a2 BCR-ABL transcript. This finding was confirmed by Southern blot analysis using a specific probe corresponding to intron 6 of the BCR gene, whereas conventional Southern blot for rearrangement of the major breakpoint cluster region (M-bcr) was negative. Western blot studies detected a BCR-ABL protein slightly larger than p185 BCR-ABL. Metaphase fluorescence in situ hybridization showed an insertion of ABL material into the BCR region without reciprocal BCR translocation. The findings in this case show that atypical BCR-ABL transcripts are detectable even in Ph- CML patients without M-bcr-rearrangements. Multiplex PCR using primers that allow for amplification of all known BCR-ABL transcripts is an appropriate method to exclude these rare variants.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8822944

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.

Authors:  Markus Pfirrmann; Dobromira Evtimova; Susanne Saussele; Fausto Castagnetti; Francisco Cervantes; Jeroen Janssen; Verena S Hoffmann; Gabriele Gugliotta; Rüdiger Hehlmann; Andreas Hochhaus; Joerg Hasford; Michele Baccarani
Journal:  J Cancer Res Clin Oncol       Date:  2017-01-12       Impact factor: 4.553

2.  BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.

Authors:  Antonella Zagaria; Luisa Anelli; Nicoletta Coccaro; Giuseppina Tota; Paola Casieri; Angelo Cellamare; Luciana Impera; Claudia Brunetti; Angela Minervini; Crescenzio Francesco Minervini; Mario Delia; Cosimo Cumbo; Paola Orsini; Giorgina Specchia; Francesco Albano
Journal:  Virchows Arch       Date:  2015-07-07       Impact factor: 4.064

3.  Chronic myeloid leukemia with insertion-derived BCR-ABL1 fusion: redefining complex chromosomal abnormalities by correlation of FISH and karyotype predicts prognosis.

Authors:  Zhenya Tang; Gokce A Toruner; Guilin Tang; C Cameron Yin; Wei Wang; Shimin Hu; Beenu Thakral; Sa A Wang; Roberto N Miranda; Joseph D Khoury; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2020-05-13       Impact factor: 7.842

4.  Characterization of the different BCR-ABL transcripts with a single multiplex RT-PCR.

Authors:  Jacques Chasseriau; Jérôme Rivet; Frédéric Bilan; Jean-Claude Chomel; François Guilhot; Nicolas Bourmeyster; Alain Kitzis
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

Review 5.  Molecular biology of chronic myeloid leukemia.

Authors:  Y Maru
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

Review 6.  Nuclear microenvironment in cancer diagnosis and treatment.

Authors:  Rossanna C Pezo; Robert H Singer
Journal:  J Cell Biochem       Date:  2008-08-15       Impact factor: 4.429

Review 7.  Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia.

Authors:  Vivian G Oehler; Jerald P Radich
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

8.  Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report.

Authors:  Livia Manzella; Elena Tirrò; Silvia Rita Vitale; Adriana Puma; Maria Letizia Consoli; Loredana Tambè; Maria Stella Pennisi; Sandra DI Gregorio; Chiara Romano; Cristina Tomarchio; Francesco DI Raimondo; Fabio Stagno
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 9.  Transient Receptor Potential (TRP) Channels in Haematological Malignancies: An Update.

Authors:  Federica Maggi; Maria Beatrice Morelli; Massimo Nabissi; Oliviero Marinelli; Laura Zeppa; Cristina Aguzzi; Giorgio Santoni; Consuelo Amantini
Journal:  Biomolecules       Date:  2021-05-20

10.  The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era.

Authors:  Ilana Zalcberg Renault; Vanesa Scholl; Rocio Hassan; Paola Capelleti; Marcos de Lima; Jorge Cortes
Journal:  Rev Bras Hematol Hemoter       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.